Aspen Neuroscience raises $140.6 million in Parkinson’s IPO
Aspen Neuroscience raised $140.6 million at $15 per share and plans a Phase 3 trial by the end of next year, before long-term data from the study arrive in 2028.
Topic
Sasineprocel
Topic
Topic
Topic
Aspen Neuroscience raised $140.6 million at $15 per share and plans a Phase 3 trial by the end of next year, before long-term data from the study arrive in 2028.